280. O Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Random- ized Survival Trial (FIRST). Am Heart J 1999;138:78 86. 281. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003;9:180 7. 282. Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobut- amine or milrinone infusions for stage D heart failure. Circ Heart Fail 2009;2:320 4. 283. Cohn JN, Goldstein SO, Greenberg BH, et al., Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339: 1810 6. 284. Hampton JR, van Veldhuisen DJ, Kleber FX, et al., Second Prospective Randomised Study of Ibopamine on Mortality and Ef cacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997;349:971 7. 285. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996;76: 223 31. 286. Packer M, Carver JR, Rodeheffer RJ, et al., the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468 75. 287. Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009;30:3015 26. 288. Oliva F, Latini R, Politi A, et al. 